Form 4: United Therapeutics EVP Sells Shares Under 10b5-1 Plan

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 8,300 shares of common stock on January 2, 2026, under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp (UTHR), executed transactions on January 2, 2026.
• Mahon exercised stock options to acquire 8,300 shares of common stock at an exercise price of $146.03 per share.
• Concurrently, Mahon sold 8,300 shares of common stock in multiple transactions.
• The sales were executed at weighted average prices ranging from $481.2596 to $489.148 per share.
• These transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on August 11, 2025.
• Following these transactions, Mahon directly beneficially owns 36,781 shares of common stock and 66,700 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it was pre-planned under a 10b5-1 plan, which mitigates concerns about opportunistic selling. The significant profit realized from the option exercise is a positive for the insider.

Positives

• The transactions were executed under a pre-arranged 10b5-1 plan, indicating a planned sale rather than a reaction to new, non-public information.
• The exercise price of $146.03 compared to sale prices ranging from $481.2596 to $489.148 indicates a significant profit for the insider.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

na

Industry Context

na

Stakeholder Impact

• Shareholders may view the insider sale as a slight negative, though the pre-planned nature under a 10b5-1 plan reduces concerns about opportunistic selling based on non-public information.

Key Dates

Recommendation

The filing reports a routine, pre-planned insider transaction (exercise of options and sale of shares) under a 10b5-1 plan. This type of transaction is generally not indicative of new material information about the company's future prospects. Therefore, it does not provide a basis for a change in investment recommendation, suggesting a 'hold' position if already invested, or 'na' if no prior position.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Paul A. Mahon, EVP, General Counsel, Share Sale